These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 21317203)
61. Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. Shankar A; Roy S; Rath GK; Julka PK; Kamal VK; Malik A; Patil J; Jeyaraj PA; Mahajan MK Asian Pac J Cancer Prev; 2015; 16(15):6359-64. PubMed ID: 26434843 [TBL] [Abstract][Full Text] [Related]
62. Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06. Villanueva C; Romieu G; Salvat J; Chaigneau L; Merrouche Y; N'guyen T; Vuillemin AT; Demarchi M; Dobi E; Pivot X Target Oncol; 2013 Jun; 8(2):137-43. PubMed ID: 23609057 [TBL] [Abstract][Full Text] [Related]
63. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. Smith IE; Walsh G; Skene A; Llombart A; Mayordomo JI; Detre S; Salter J; Clark E; Magill P; Dowsett M J Clin Oncol; 2007 Sep; 25(25):3816-22. PubMed ID: 17679728 [TBL] [Abstract][Full Text] [Related]
65. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Isaacs C; Herbolsheimer P; Liu MC; Wilkinson M; Ottaviano Y; Chung GG; Warren R; Eng-Wong J; Cohen P; Smith KL; Creswell K; Novielli A; Slack R Breast Cancer Res Treat; 2011 Jan; 125(1):137-43. PubMed ID: 20976541 [TBL] [Abstract][Full Text] [Related]
66. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Carlini P; Frassoldati A; De Marco S; Casali A; Ruggeri EM; Nardi M; Papaldo P; Fabi A; Paoloni F; Cognetti F Ann Oncol; 2001 Nov; 12(11):1539-43. PubMed ID: 11822752 [TBL] [Abstract][Full Text] [Related]
67. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. Iwamoto T; Fujisawa T; Shien T; Araki K; Sakamaki K; Sangai T; Kikawa Y; Takao S; Nishimura R; Takahashi M; Aihara T; Mukai H; Taira N Breast Cancer; 2020 Sep; 27(5):973-981. PubMed ID: 32394413 [TBL] [Abstract][Full Text] [Related]
68. Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. Balduzzi A; Bagnardi V; Sandri MT; Dellapasqua S; Cardillo A; Montagna E; Cancello G; Iorfida M; Ghisini R; Viale G; Intra M; Luini A; Goldhirsch A; Colleoni M Clin Breast Cancer; 2015 Oct; 15(5):e257-62. PubMed ID: 26362840 [TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Zhu ZL; Zhang J; Chen ML; Li K Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260 [TBL] [Abstract][Full Text] [Related]
70. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Mayer EL; Baurain JF; Sparano J; Strauss L; Campone M; Fumoleau P; Rugo H; Awada A; Sy O; Llombart-Cussac A Clin Cancer Res; 2011 Nov; 17(21):6897-904. PubMed ID: 21903773 [TBL] [Abstract][Full Text] [Related]
71. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822 [TBL] [Abstract][Full Text] [Related]
72. [Therapeutic advances in breast cancer]. Pestalozzi BC Ther Umsch; 2006 Apr; 63(4):255-61. PubMed ID: 16689456 [TBL] [Abstract][Full Text] [Related]
73. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Shimoi T; Sagara Y; Hara F; Toyama T; Iwata H Breast Cancer; 2020 May; 27(3):340-346. PubMed ID: 32043218 [TBL] [Abstract][Full Text] [Related]
74. [Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms]. Grell P; Svoboda M; Simícková M; Fabian P; Vyzula R Klin Onkol; 2009; 22(2):45-51. PubMed ID: 19522373 [TBL] [Abstract][Full Text] [Related]
75. [BOLERO -- another remarkable step in treatment of breast cancer]. Rubovszky G; Láng I Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761 [TBL] [Abstract][Full Text] [Related]
76. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697 [TBL] [Abstract][Full Text] [Related]
77. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Cheung KL; Agrawal A; Folkerd E; Dowsett M; Robertson JF; Winterbottom L Eur J Cancer; 2010 Nov; 46(16):2936-42. PubMed ID: 20832294 [TBL] [Abstract][Full Text] [Related]